A detailed history of Jpmorgan Chase & CO transactions in Alvotech stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,709 shares of ALVO stock, worth $20,354. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,709
Previous 4,368 60.87%
Holding current value
$20,354
Previous $53,000 62.26%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$10.76 - $12.99 $28,610 - $34,540
-2,659 Reduced 60.87%
1,709 $20,000
Q2 2024

Aug 12, 2024

BUY
$11.4 - $14.51 $46,363 - $59,012
4,067 Added 1351.16%
4,368 $53,000
Q1 2024

May 10, 2024

BUY
$11.36 - $17.27 $3,419 - $5,198
301 New
301 $3,000
Q3 2023

Nov 14, 2023

SELL
$8.12 - $10.07 $420,477 - $521,454
-51,783 Reduced 85.98%
8,446 $77,000
Q2 2023

Aug 11, 2023

BUY
$6.9 - $13.85 $412,137 - $827,260
59,730 Added 11969.94%
60,229 $466,000
Q1 2023

May 11, 2023

BUY
$10.01 - $14.03 $4,994 - $7,000
499 New
499 $6,000

Others Institutions Holding ALVO

About Alvotech


  • Ticker ALVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 248,650,000
  • Market Cap $2.96B
  • Description
  • Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...
More about ALVO
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.